Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Current Assets (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Current Assets data on record, last reported at $413.8 million in Q3 2025.

  • For Q3 2025, Current Assets rose 43.94% year-over-year to $413.8 million; the TTM value through Sep 2025 reached $413.8 million, up 43.94%, while the annual FY2024 figure was $280.9 million, 58.3% up from the prior year.
  • Current Assets reached $413.8 million in Q3 2025 per DNTH's latest filing, up from $263.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $413.8 million in Q3 2025 and bottomed at $78.6 million in Q2 2023.
  • Average Current Assets over 4 years is $220.7 million, with a median of $191.5 million recorded in 2023.
  • Peak YoY movement for Current Assets: crashed 47.93% in 2023, then skyrocketed 365.03% in 2024.
  • A 4-year view of Current Assets shows it stood at $82.0 million in 2022, then skyrocketed by 116.32% to $177.5 million in 2023, then soared by 58.3% to $280.9 million in 2024, then skyrocketed by 47.32% to $413.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $413.8 million in Q3 2025, $263.6 million in Q2 2025, and $271.0 million in Q1 2025.